Author

Aaron Broege

Observed names: A. Broege, Aaron M Broege

Observed institutions: University of Minnesota, Carleton College, University of Minnesota System

OpenAlex ID: A5027105192

Bone Morphogenetic Proteins Signal Via SMAD and Mitogen-activated Protein (MAP) Kinase Pathways at Distinct Times during Osteoclastogenesis

2013 · Aaron Broege, Lan Pham, et al. · Journal of Biological Chemistry · 63

PDF

Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models

2024 · Stefano Rossetti, Aaron Broege, et al. · npj Breast Cancer · 33

Loss of the nutrient sensor TAS1R3 leads to reduced bone resorption

2017 · Michael S. Eaton, Nicholas Weinstein, et al. · Journal of Physiology and Biochemistry · 28

Smad1/5 and Smad4 Expression Are Important for Osteoclast Differentiation

2015 · Amy Tasca, Melissa Stemig, et al. · Journal of Cellular Biochemistry · 25

Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway

2024 · Adrish Sen, Salmaan Khan, et al. · Molecular Oncology · 16

PDF

Functional Analysis of the PI3K/AKT/mTOR Pathway Inhibitor, Gedatolisib, Plus Fulvestrant with and Without Palbociclib in Breast Cancer Models

2025 · Aaron Broege, Stefano Rossetti, et al. · International Journal of Molecular Sciences · 12

PDF

Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib

2024 · Aaron Broege, Stefano Rossetti, et al. · Cancers · 9

PDF

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.

2023 · Adrish Sen, Salmaan A Khan, et al. · Journal of Clinical Oncology · 2

Abstract 342: Sub-group of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

2021 · Salmaan Khan, Adrish Sen, et al. · Cancer Research · 2

Abstract PS2-11-30: Functional analysis of gedatolisib combined with fulvestrant and/or palbociclib in breast cancer cell models adapted to estrogen receptor and/or CDK4/6 inhibitors

2026 · S. Rossetti, A. Broege, et al. · Clinical Cancer Research · 1

Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status

2023 · Stefano Rossetti, Aaron Broege, et al. · Cancer Research · 1

Abstract 367: Sub-group of ovarian cancer patients with hyperactive RAS network signaling identified: Dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

2021 · Stefano Rossetti, Aaron Broege, et al. · Cancer Research · 1

Test identifies ovarian cancer patients with hyperactive c-Met and ErbB signaling tumors who may benefit from c-Met and pan-HER combination therapy.

2020 · Lance G. Laing, Stefano Rossetti, et al. · Journal of Clinical Oncology · 1

Abstract P2-02-07: Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions

2025 · Stefano Rossetti, Aaron Broege, et al. · Clinical Cancer Research

Abstract P2-02-05: Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models

2025 · Stefano Rossetti, Aaron Broege, et al. · Clinical Cancer Research

Author response for "Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway"

2024 · Adrish Sen, Salmaan Khan, et al. · Publons reviews and discussion

Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models

2024 · Stefano Rossetti, Aaron Broege, et al. · Cancer Research

Abstract 3198: Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

2020 · Stefano Rossetti, Catherine Kuzmicki, et al. · Cancer Research

Transcriptional regulation of transcription Factor 8

2010 · Aaron Broege · University of Minnesota Digital Conservancy (University of Minnesota)

PDF

Works count: 19

Citation count: 194

H-index: 7

I10-index: 6